Basic Information
| LncRNA/CircRNA Name | SPRY4-IT1 |
| Synonyms | SPRY4-IT1, SPRIGHTLY |
| Region | NA |
| Ensemble | ENSG00000281881 |
| Refseq | NR_131221 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cholangiocarcinoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP etc. |
| Sample | cholangiocarcinoma tissues, cell lines (HIBEC, CCLP-1, HuCCT1, Huh-28, KMBC and QBC939) |
| Expression Pattern | up-regulated |
| Function Description | SPRY4-IT1 was abnormally upregulated in CCA tissues and cells, and this upregulation was correlated with tumor stage and tumor node metastasis (TNM) stage in CCA patients. SPRY4-IT1 overexpression was also an unfavorable prognostic factor for patients with CCA. Additionally,SP1 could bind directly to the SPRY4-IT1 promoter region and activate its transcription. Mechanistically, enhancer of zeste homolog 2 (EZH2) along with the lysine specific demethylase 1 (LSD1) or DNA methyltransferase 1 (DNMT1) were recruited by SPRY4-IT1, which functioned as a scaffold.Importantly, SPRY4-IT1 positively regulated the expression of EZH2 through sponging miR-101-3p. |
| Pubmed ID | 29642935 |
| Year | 2018 |
| Title | SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. |
External Links
| Links for SPRY4-IT1 | GenBank HGNC NONCODE |
| Links for cholangiocarcinoma | OMIM COSMIC |